01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Background
Methods
Statistical analyses
Results
Median age (years)
|
66.0
|
Menopausal status
|
|
Premenopausal
|
2 (4.7%)
|
Postmenopausal
|
39 (90.7%)
|
Not confirmed
|
2 (4.7%)
|
T class
|
|
T1
|
29 (67.4%)
|
T2
|
11 (25.6%)
|
T3
|
2 (4.7%)
|
T4
|
1 (2.3%)
|
Mean size of primary tumor, mm (95% CI)
|
25.3 (18.9-31.7)
|
N class
|
|
N0
|
24 (55.8%)
|
N1
|
10 (23.3%)
|
N2
|
5 (11.6%)
|
N3
|
2 (4.7%)
|
Missing
|
2 (4.7%)
|
Mean number of lymph node metastases (95% CI)
|
2.2 (0.4-3.9)
|
Primary distant metastases
|
|
No
|
39 (90.7%)
|
Yes
|
4 (9.3%)
|
HER2 expression
|
|
Negative
|
40 (93.0%)
|
Positive
|
2 (4.7%)
|
Missing
|
1 (2.3%)
|
Estrogen receptor expression
|
|
Negative (0%)
|
1 (2.3%)
|
Low (1-9%)
|
0 (0%)
|
Moderate (10-59%)
|
0 (0%)
|
High (>60%)
|
41 (97.7%)
|
Missing
|
1 (2.3%)
|
Progesterone receptor expression
|
|
Negative (0%)
|
4 (9.3%)
|
Low (1-9%)
|
6 (14.0%)
|
Moderate (10-59%)
|
6 (14.0%)
|
High (>60%)
|
25 (58.1%)
|
Missing
|
2 (4.7%)
|
Ki-67 expression
|
|
Negative (<5%)
|
1 (2.3%)
|
Low (5-14%)
|
14 (32.6%)
|
Moderate (15-30%)
|
15 (34.9%)
|
High (>30%)
|
11 (25.6%)
|
Missing
|
2 (4.7%)
|
Multifocal disease
|
|
Yes
|
15 (35.9%)
|
No
|
28 (65.1%)
|
Synaptophysin expression
|
|
Yes
|
43 (100%)
|
No
|
0 (0%)
|
Chromogranin expression
|
|
Yes
|
30 (69.8%)
|
No
|
9 (20.9%)
|
Not available
|
4 (9.3%)
|
NEBC (
n = 39)
|
Ductal carcinomas (
n = 506)
|
p-value
|
|
---|---|---|---|
Median age at diagnosis
|
66.0
|
57.0
|
<0.0005
|
T class
|
0.40
|
||
T1
|
28 (71.8%)
|
322 (63.6%)
|
|
T2
|
9 (23.1%)
|
167 (33.0%)
|
|
T3
|
2 (5.1%)
|
12 (2.4%)
|
|
T4
|
0 (0.0%)
|
5 (1.0%)
|
|
N class
|
0.72
|
||
N0
|
23 (59.0%)
|
314 (62.1%)
|
|
N1
|
10 (25.6%)
|
149 (29.4%)
|
|
N2
|
5 (12.8%)
|
41 (8.1%)
|
|
N3
|
0 (0.0%)
|
2 (0.4%)
|
|
Missing
|
1 (2.6%)
|
0 (0.0%)
|
|
HER2 expression
|
0.046
|
||
Negative
|
37 (94.9%)
|
437 (86.4%)
|
|
Positive
|
1 (2.6%)
|
69 (13.6%)
|
|
Missing
|
1 (2.6%)
|
0 (0.0%)
|
|
Estrogen receptor expression
|
0.0062
|
||
Negative
|
1 (2.6%)
|
103 (20.4%)
|
|
Low
|
0 (0.0%)
|
18 (3.6%)
|
|
Moderate
|
0 (0.0%)
|
25 (4.9%)
|
|
High
|
37 (94.9%)
|
360 (71.1%)
|
|
Missing
|
1 (2.6%)
|
0 (0.0%)
|
|
Progesterone receptor expression
|
0.088
|
||
Negative
|
4 (10.3%)
|
148 (29.2%)
|
|
Low
|
4 (10.3%)
|
61 (12.1%)
|
|
Moderate
|
5 (12.8%)
|
57 (11.3%)
|
|
High
|
25 (61.5%)
|
240 (47.4%)
|
|
Missing
|
2 (5.1%)
|
0 (0.0%)
|
|
Ki-67
|
0.060
|
||
Negative
|
0 (0.0%)
|
32 (6.3%)
|
|
Low
|
14 (35.9%)
|
217 (43.1%)
|
|
Moderate
|
15 (38.5%)
|
116 (23.0%)
|
|
High
|
8 (20.5%)
|
139 (27.6%)
|
|
Missing
|
2 (5.1%)
|
2 (0.4%)
|
|
Adjuvant radiotherapy
|
0.23
|
||
No
|
8 (20.5%)
|
66 (13.4%)
|
|
Yes
|
31 (79.5%)
|
427 (86.6%)
|
|
Adjuvant chemotherapy
|
0.00070
|
||
No
|
27 (69.2%)
|
207 (40.2%)
|
|
Yes
|
12 (30.8%)
|
299 (59.1%)
|
|
Adjuvant endocrine therapy
|
0.015
|
||
No
|
7 (17.9%)
|
191 (37.7%)
|
|
Yes
|
32 (82.1%)
|
315 (62.3%)
|